Medicines to prolong the life of lung cancer patients, as well as treatments for osteoporosis and drug-resistant infections, have been approved under a new €20m deal by the HSE.
In a small study, patients treated with romosozumab had a greater increase in spine bone mineral density, compared with the denosumab group after 1 year.
Experts agree that there is no evidence that any osteoporosis therapy either increases the risk or severity of COVID-19 infection, alters the disease course, or interferes with the efficacy or side effect profile of COVID-19 vaccination. However, considering limited COVID-19 vaccine availability, vaccinations may need to be prioritized and alterations made in standard osteoporosis regimens. Patients are urged to consult with their health care providers before making any alterations in the osteoporosis regimens. General bone health measures (i.e., calcium and vitamin D supplementation, weight-bearing exercises, and maintenance of a balanced diet) should not be interrupted at the time of vaccination or thereafter.